Takeda Pharmaceutical Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of neonatal-onset multisystem inflammatory disease (NOMID/CINCA), Muckle-Wells syndrome, familial cold autoinflammatory syndrome, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and prion disease.

Rockefeller University has disclosed non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Chengdu Duote Antibody Pharmaceutical Co. Ltd. has described antibody-drug conjugates comprising antibody or antigen-binding fragments covalently linked to eribulin derivatives through a linker reported to be useful for the treatment of cancer.

Nanjing Mingde New Drug Research Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety via linker. They are reported to be useful for the treatment of breast cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and derived PROTAC compounds reported to be useful for the treatment of autoimmune disorders, inflammatory disorders, cancer, transplant rejection and more.

Beijing Zheyuan Technology Co. Ltd. has synthesized serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer and sepsis.

Suzhou Zion Pharma Technology Co. Ltd. has disclosed GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described GTPase KRAS mutant inhibitors, particularly KRAS G12C mutant, reported to be useful for the treatment of cancer.

Shenzhen Crystalo Biopharma Technology Co. Ltd. has divulged short transient receptor potential channel 5 (TRPC5) antagonists reported to be useful for the treatment of anxiety, depression, post-traumatic stress, diabetic nephropathy and focal segmental glomerulosclerosis.

Boehringer Ingelheim Pharma GmbH & Co KG has identified drug conjugates acting as neuromedin U receptor 2 (NMU2) agonists reported to be useful for the treatment of obesity.